Millennium Management LLC Sells 302,064 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN)

Millennium Management LLC decreased its stake in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 45.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 365,972 shares of the company's stock after selling 302,064 shares during the quarter. Millennium Management LLC owned about 0.46% of Viridian Therapeutics worth $7,016,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in the stock. Barclays PLC raised its stake in shares of Viridian Therapeutics by 113.1% in the third quarter. Barclays PLC now owns 125,397 shares of the company's stock worth $2,851,000 after purchasing an additional 66,550 shares during the last quarter. SG Americas Securities LLC raised its stake in shares of Viridian Therapeutics by 89.1% in the fourth quarter. SG Americas Securities LLC now owns 31,085 shares of the company's stock worth $596,000 after purchasing an additional 14,644 shares during the last quarter. Moody Aldrich Partners LLC purchased a new position in shares of Viridian Therapeutics in the fourth quarter worth $1,125,000. Vanguard Group Inc. raised its stake in shares of Viridian Therapeutics by 4.0% in the fourth quarter. Vanguard Group Inc. now owns 4,595,049 shares of the company's stock worth $88,087,000 after purchasing an additional 174,952 shares during the last quarter. Finally, Principal Financial Group Inc. raised its stake in shares of Viridian Therapeutics by 3.3% in the fourth quarter. Principal Financial Group Inc. now owns 178,444 shares of the company's stock worth $3,421,000 after purchasing an additional 5,634 shares during the last quarter.

Viridian Therapeutics Stock Performance

Viridian Therapeutics stock traded down $0.18 during mid-day trading on Friday, reaching $13.79. 768,725 shares of the stock traded hands, compared to its average volume of 1,192,614. The stock has a market capitalization of $1.13 billion, a PE ratio of -3.20 and a beta of 0.57. The company has a debt-to-equity ratio of 0.04, a current ratio of 18.55 and a quick ratio of 18.55. Viridian Therapeutics, Inc. has a 12-month low of $9.90 and a 12-month high of $27.20. The business's 50-day moving average is $13.02 and its 200-day moving average is $16.45.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The company reported ($0.87) EPS for the quarter, beating analysts' consensus estimates of ($0.95) by $0.08. The company had revenue of $0.07 million during the quarter, compared to analysts' expectations of $0.16 million. Viridian Therapeutics had a negative return on equity of 70.12% and a negative net margin of 85,127.16%. The business's revenue for the quarter was up .0% on a year-over-year basis. As a group, sell-side analysts predict that Viridian Therapeutics, Inc. will post -4.03 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms have recently weighed in on VRDN. Needham & Company LLC restated a "buy" rating and issued a $36.00 price target on shares of Viridian Therapeutics in a research note on Tuesday, May 20th. JMP Securities decreased their price target on Viridian Therapeutics from $42.00 to $38.00 and set a "market outperform" rating for the company in a research note on Wednesday, May 7th. The Goldman Sachs Group decreased their price target on Viridian Therapeutics from $31.00 to $27.00 and set a "buy" rating for the company in a research note on Wednesday, May 7th. Royal Bank of Canada decreased their price target on Viridian Therapeutics from $46.00 to $45.00 and set an "outperform" rating for the company in a research note on Wednesday, May 7th. Finally, HC Wainwright restated a "buy" rating and issued a $34.00 price target on shares of Viridian Therapeutics in a research note on Wednesday, April 23rd. One investment analyst has rated the stock with a hold rating and ten have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $36.70.

About Viridian Therapeutics

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.